Kythera Biopharmaceuticals Presents Positive Magnetic Resonance Imaging (MRI) Results From Phase IIb Study of ATX-101 in the Reduction of Submental Fat or "Double Chin"

NEW YORK--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today presented positive results that found MRI measurements of patients treated with ATX-101 demonstrated a statistically significant reduction in submental fat (SMF), commonly known as double chin, during an oral session at The Aesthetic Meeting 2013, organized by the American Society for Aesthetic Plastic Surgery (ASAPS), April 11-16, New York, NY. MRI assessments were performed in the study as a quantifiable and objective measure of submental fat volume and thickness. The same study also demonstrated positive results based on validated clinician- and patient-reported outcome measures. The results are from a Phase IIb, multicenter, randomized, double-blind, placebo-controlled study (ATX-101-09-15) to evaluate the safety and efficacy of ATX-101, a potential first-in-class, non-surgical, injectable drug currently in Phase III clinical trials in the U.S. and Canada for the reduction of SMF.